Long-term survival of renal transplant recipients in the United States after acute myocardial infarction

2000 ◽  
Vol 36 (1) ◽  
pp. 145-152 ◽  
Author(s):  
Charles A. Herzog ◽  
Jennie Z. Ma ◽  
Allan J. Collins
Keyword(s):  
United States ◽  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Renal Transplant ◽  
The United States ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Long-term survival in renal transplant recipients with graft function

2000 ◽  
Vol 57 (1) ◽  
pp. 307-313 ◽  
Author(s):  
Akinlolu O. Ojo ◽  
Julie A. Hanson ◽  
Robert A. Wolfe ◽  
Alan B. Leichtman ◽  
Lawrence Y. Agodoa ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Graft Function ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Term Survival ◽  
Long Term Survival

Effect of Immunosuppressive Agents on Long-Term Survival of Renal Transplant Recipients

Drugs ◽  
2004 ◽  
Vol 64 (18) ◽  
pp. 2047-2073 ◽  
Author(s):  
Johannes M M Boots ◽  
Maarten H L Christiaans ◽  
Johannes P van Hooff
Keyword(s):  
Renal Transplant ◽  
Immunosuppressive Agents ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Long-term survival benefit of ramipril in patients with acute myocardial infarction complicated by heart failure

Heart ◽  
2021 ◽  
Vol 107 (5) ◽  
pp. 389-395
Author(s):  
Jianhua Wu ◽  
Alistair S Hall ◽  
Chris P Gale
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Acute Myocardial Infarction ◽  
Life Expectancy ◽  
Survival Benefit ◽  
Ace Inhibition ◽  
Survival Times ◽  
Term Survival ◽  
Long Term Survival

AimsACE inhibition reduces mortality and morbidity in patients with heart failure after acute myocardial infarction (AMI). However, there are limited randomised data about the long-term survival benefits of ACE inhibition in this population.MethodsIn 1993, the Acute Infarction Ramipril Efficacy (AIRE) study randomly allocated patients with AMI and clinical heart failure to ramipril or placebo. The duration of masked trial therapy in the UK cohort (603 patients, mean age=64.7 years, 455 male patients) was 12.4 and 13.4 months for ramipril (n=302) and placebo (n=301), respectively. We estimated life expectancy and extensions of life (difference in median survival times) according to duration of follow-up (range 0–29.6 years).ResultsBy 9 April 2019, death from all causes occurred in 266 (88.4%) patients in placebo arm and 275 (91.1%) patients in ramipril arm. The extension of life between ramipril and placebo groups was 14.5 months (95% CI 13.2 to 15.8). Ramipril increased life expectancy more for patients with than without diabetes (life expectancy difference 32.1 vs 5.0 months), previous AMI (20.1 vs 4.9 months), previous heart failure (19.5 vs 4.9 months), hypertension (16.6 vs 8.3 months), angina (16.2 vs 5.0 months) and age >65 years (11.3 vs 5.7 months). Given potential treatment switching, the true absolute treatment effect could be underestimated by 28%.ConclusionFor patients with clinically defined heart failure following AMI, ramipril results in a sustained survival benefit, and is associated with an extension of life of up to 14.5 months for, on average, 13 months treatment duration.

scholarly journals Long-term Survival of Dialysis Patients With Bacterial Endocarditis Undergoing Valvular Replacement Surgery in the United States

Circulation ◽  
2013 ◽  
Vol 128 (4) ◽  
pp. 344-351 ◽  
Author(s):  
Maxwell D. Leither ◽  
Gautam R. Shroff ◽  
Shu Ding ◽  
David T. Gilbertson ◽  
Charles A. Herzog
Keyword(s):  
United States ◽  
The United States ◽  
Bacterial Endocarditis ◽  
Dialysis Patients ◽  
Term Survival ◽  
Long Term Survival ◽  
Replacement Surgery ◽  
Valvular Replacement
Sign in / Sign up

Export Citation Format

Share Document